Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles.
Liquisolid systems were originally designed to enhance dissolution of hydrophobic drugs. Recently, the same technique was explored to control drug release via hydrophobic carriers. This work aimed to study the effects of different liquid vehicles on release characteristics of griseofulvin as a model hydrophobic drug. Fast dissolution tablets were prepared using three different non-ionic surfactants namely Cremophor(®)EL, Synperonic(®)PE/L61 and Capryol™ 90, on the contrary Kollicoat(®)SR 30D was used for production of grieseofulvin sustained release formulations. Avicel(®) PH102 and Cab-O-Sil(®) M5 were used as carrier and coat materials, respectively. The effect of formulation parameters, such as drug concentration and carrier to coat ratio, on enhancing drug dissolution was explored. Drug concentrations of 20% and 40% (w/w), and R-values (carrier to coat ratio) of 10 and 20 were used. The mathematical model was utilized to formulate liquisolid powder systems. All fast release liquisolid formulations showed higher percentage drug dissolution efficiency (%DE) than conventional directly compacted tablets. Cremophor(®)EL showed the best dissolution enhancement with %DE of about 90%, compared to only 23% for conventional tablets; DSC data suggested loss of griseofulvin crystallinity and thermal behavior. Kollicoat(®) SR 30D retarded the drug release even in the presence of hydrophilic carrier; DSC data suggested that only small fraction of the drug was present in the molecular state within the system. The used liquisolid vehicles showed promise to enhance and to control (depend on the choice of the liquid vehicle) the release of griseofulvin from liquisolid compacts.
University of Sunderland, Department of Pharmacy, Health and Well-being, Sunderland, SR1 3SD, UK. amal.elkordy@sunderland.ac.uk
Amal Ali
AA
Elkordy
Ebtessam Ahmed
EA
Essa
Shreyas
S
Dhuppad
Poojitha
P
Jammigumpula
D002626:Chemistry, Pharmaceutical; D003460:Crystallization; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D005079:Excipients / Q000737:chemistry*; D006118:Griseofulvin / Q000008:administration & dosage / Q000737:chemistry*; D057927:Hydrophobic and Hydrophilic Interactions; D008962:Models, Theoretical; D014677:Pharmaceutical Vehicles / Q000737:chemistry; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry*; D013607:Tablets; D013997:Time Factors
D004337:Drug Carriers; D005079:Excipients; D014677:Pharmaceutical Vehicles; D013501:Surface-Active Agents; D013607:Tablets; D006118:Griseofulvin